Oral ibrexafungerp efficacy and safety in the treatment of vulvovaginal candidiasis: A phase 3, randomized, blinded, study vs. placebo (VANISH-303)

We present the first of two phase 3 studies evaluating the safety and efficacy of oral ibrexafungerp in VVC.

Source: American Journal of Obstetrics and Gynecology - November 24, 2020 Category: OBGYN Authors: J.R. Schwebke, V. Sorkin-Wells, N. Azie, D. Angulo, J. Sobel Tags: IDSOG Oral Presentation Source Type: research